tebentafusp + tremelimumab

Tebentafusp + tremelimumab is a **combination immunotherapy regimen** being explored for the treatment of advanced melanoma, particularly metastatic cutaneous melanoma. Tebentafusp is a first-in-class bispecific fusion protein (ImmTAC) that redirects T cells to target glycoprotein 100 (gp100) presented by HLA-A*02:01 on melanoma cells, engaging CD3 on T lymphocytes to trigger an anti-tumor immune response. Tebentafusp is an ImmTAC, consisting of a soluble TCR fused to an anti-CD3 scFv. Tremelimumab is a fully human IgG2 monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), functioning as an immune checkpoint inhibitor to enhance T cell activation and proliferation. The combination leverages the tumor-targeting capability of tebentafusp and the broad immune activation of tremelimumab to potentially overcome resistance in patients who have progressed on prior immunotherapies[1][2][3].